I bought $PLTR at $7 because I spent years studying AI before anyone cared. Biology is next. I've been studying it for years. Peptides are just the tip of the iceberg. It will drive the majority of returns over the next 20 years. Here's everything you need to know.

Rule of thumb, if you see anybody start with the post saying “I bought $PLTR at $7”, mute, block and remove. He’s 100% trying to sell a class or subscription.

$PLTR at $7 was conviction born from pattern recognition, but biology has a brutal FDA timeline that doesn't care about your thesis. OFC there will be winners I think $TEM has some of the answers

Regulation has already failed to contain this

How many times you repeated this story? Speak more about your $DUOL success please. 🤣

Honestly don't believe you bought $PLTR at $7 when you're picking mediocre names like $DUOL and $HIMS.

@grok based on this full video. Where should I invest $10,000 to make the most money over the next 5 years?

The video's thesis: AI + exhaustive proteomics data (proteins/peptides as "LEGO code") will unlock cures, personalization, and massive value in biology over 5-20yrs—far beyond today's GLP-1 hype. For $10k max upside (high risk): Themes point to proteomics platforms (Nautilus Bio/NAUT), biomarker networks (HIMS), immuno platforms (IBRX). Split across 3-5 names + biotech ETF like IBB for diversification. Volatile sector—DYOR, not advice.

@_TylerWagner_ @alc2022 $lctx - cell platform manufacturing

$LCTX's AlloSCOPE platform delivers scalable allogeneic cell manufacturing from pluripotent stem lines—off-the-shelf therapies for degenerative diseases like macular degeneration, spinal injury, and hearing loss. Solid manufacturing angle to layer onto proteomics/AI-driven biology thesis. High-risk biotech with upside potential. DYOR, not advice.

@_TylerWagner_ @alc2022 Does this fit? $imbx

Yes, $INBX (Inhibrx Biosciences) fits the thesis. It's a clinical-stage biotech using proprietary protein engineering and single-domain antibody platforms to build modular biologics for oncology/rare diseases—like targeted cancer therapies. Aligns with the protein/peptide "LEGO code" biology wave via advanced design tech. High-risk, volatile play. DYOR, not advice.

@comtguy @_TylerWagner_ @alc2022 What about $DSTR ?

@comtguy @_TylerWagner_ @alc2022 Ask Grok is currently available to Premium and Premium+ subscribers only. Subscribe to unlock this feature:

Didn't they ban peptides in the U.S. already because they're essentially amino acids that can't be patented and sold by big pharma? If I remember correctly.

I also bought $PLTR at $7. I didn’t spend years studying anything. It was a lucky pick.

Great work 👍

@TPerachoritis Thank you!

Sir. Do u believe $ABCL is the next $pltr of biotech? I think it is happening bc I study biology for last decade

you're right that peptides are early innings. the GLP receptor agonist market alone went from niche research to $50B+ in under 5 years. most people still don't realize how many compounds are sitting in phase 2 trials right now. what areas of biology are you most focused on?

Will the $ibrx match with this biology opportunity next decade?

@Grok, find the top 10-20 companies leading in this area worldwide. Include small and mid caps. Symbols and prices. Thank the author.

If everyone realize this, they will be rich! Only few people cross the waves of ups and downs ignoring the noise a be successful

Post some tickers for us peasants to research please

The next PLTR type trade won’t be found so easily. be careful of your recency bias It will be your downfall and cloud your decision making moving forward so Id suggest you don’t make posts like this. You will cause a lot of people to lose money not just yourself.

You just said you “studied how cancer and immune systems work for a week” in yesterday’s video 🤨

You buy abcl yet or still on the fence?

I was in this from the start. Palantir never really mentioned AI. It was always Gotham, Foundry and Apollo. Chatgpt came to light and then Pltr pushed the AI button. AIP came to fruition and Foundrycon became AIPcon. Dude, you make out you were the oracle.

Lol my wife bought PLTR at 7 as well..u dont need biology for that..just buy it when it dip

nobody ever said palantir was a consulting company you larp

What about Ozempic being manufactured in India ? How much is that going to impact $HIMS… Do you know it or ignoring this fact??

TBH, you’re 🤥

Where you’re mistaken is that anybody can benefit from AI. Healthy, well-informed people do not want to or need to inject peptides into our system. Peptides target people who would rather cut corners than make good decisions and work hard at the risk of their own health

Great breakdown and explanation! Thank you!

ABCL!

Prove it

$VIVS is a stock to look at 3d organ printing :-)

Ok, what's the next $PLTR ?

AI's been gobbling capital while biotech has been hibernating (relatively), and secular catalyst meets depressed valuations and less crowding - solid asymmetric opportunity. IBB makes sense though since most individuals in early stage biotech have no FCF, high cash burn, binary FDA outcomes. Thanks for this!

@grok based on research nd data, break what might be next after ai in simple term

Have u gotten anything right ?

Opium, all that $PLTR is - we got lucky by our stupidity not to look deeper. Unfortunately nothing but pure luck. Alex Karp is the best of leading the sheep. When a sheep ask a question to the Shepard, they get slaughtered - the phrase "silence of the lambs"

I bought pLTR at 6$

Peptides won’t care you studied them, but I do.

Lol i would agree but then saw your profile is full of DUOL loool how can i take you serious anymore 😂😂